Your browser is no longer supported. Please, upgrade your browser.
MYL Mylan N.V. daily Stock Chart
MYL [NASD]
Mylan N.V.
IndexS&P 500 P/E25.72 EPS (ttm)1.24 Insider Own0.68% Shs Outstand514.50M Perf Week4.50%
Market Cap16.38B Forward P/E6.31 EPS next Y5.05 Insider Trans0.00% Shs Float512.11M Perf Month8.82%
Income652.90M PEG4.98 EPS next Q1.36 Inst Own87.80% Short Float1.20% Perf Quarter-10.96%
Sales11.59B P/S1.41 EPS this Y66.60% Inst Trans0.74% Short Ratio1.35 Perf Half Y-15.81%
Book/sh23.45 P/B1.36 EPS next Y8.80% ROA1.60% Target Price41.67 Perf Year-22.98%
Cash/sh0.99 P/C32.05 EPS next 5Y5.17% ROE4.30% 52W Range26.03 - 44.18 Perf YTD16.20%
Dividend- P/FCF8.43 EPS past 5Y-0.10% ROI4.80% 52W High-27.93% Beta1.54
Dividend %- Quick Ratio0.80 Sales past 5Y11.90% Gross Margin40.60% 52W Low22.30% ATR0.82
Employees35000 Current Ratio1.30 Sales Q/Q-4.20% Oper. Margin9.10% RSI (14)62.43 Volatility2.28% 2.74%
OptionableYes Debt/Eq1.20 EPS Q/Q83.00% Profit Margin4.70% Rel Volume0.65 Prev Close31.52
ShortableYes LT Debt/Eq1.10 EarningsFeb 26 AMC Payout0.00% Avg Volume4.53M Price31.84
Recom1.80 SMA205.88% SMA507.94% SMA200-8.92% Volume2,943,967 Change1.02%
Jan-23-19Downgrade UBS Buy → Neutral
Nov-15-18Upgrade Argus Hold → Buy
Nov-06-18Upgrade BofA/Merrill Neutral → Buy
Oct-09-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-05-18Downgrade Mizuho Buy → Neutral
Aug-24-18Upgrade Evercore ISI In-line → Outperform
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Mar-15-18Reiterated Mizuho Buy $45 → $51
Mar-06-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-25-18Reiterated Susquehanna Positive $47 → $55
Jan-04-18Reiterated Citigroup Buy $48 → $58
Jan-03-18Initiated Leerink Partners Mkt Perform $44
Dec-12-17Initiated Guggenheim Buy $59
Nov-07-17Reiterated RBC Capital Mkts Sector Perform $32 → $37
Oct-04-17Reiterated BTIG Research Buy $42 → $45
Aug-22-17Downgrade Argus Buy → Hold
Aug-16-17Upgrade Citigroup Neutral → Buy
Aug-07-17Reiterated Morgan Stanley Equal-Weight $52 → $36
Jun-16-17Initiated Cantor Fitzgerald Neutral $41
Feb-15-19 04:35PM  Mylan Inc. -- Moody's announces completion of a periodic review of ratings of Mylan N.V. Moody's
10:29AM  Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates Zacks
Feb-14-19 10:02AM  Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise Zacks
Feb-12-19 11:01AM  Mylan launches Advair generic at one-third price Reuters
10:00AM  Mylan Launches Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder), at a List Price 70% Less than the Brand PR Newswire
Feb-11-19 10:24AM  Mylan to Release 2018 Fourth Quarter and Full Year Results and 2019 Guidance on Feb. 26, 2019 PR Newswire
10:17AM  Goldman Sachs pulls plug on 2-year-old, market-beating recommendation Yahoo Finance
Feb-08-19 05:13PM  Teva (TEVA) to Report Q4 Earnings: What's in the Cards? Zacks
09:53AM  Pfizer Japan recalls high blood pressure drug over cancer-causing impurity Reuters
Feb-07-19 04:11PM  Why Biogen's 'Battle-Tested' MS Drug Could Win Another Patent Dispute Investor's Business Daily
03:12PM  5 Undervalued Stocks to Invest In InvestorPlace
01:29PM  Biogen Stock Slips on a Setback in a Patent Dispute With Mylan Barrons.com
09:00AM  Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19 Zacks
Feb-03-19 09:01AM  A War on High Drug Prices Could Boost Biosimilars Motley Fool
Feb-01-19 05:58PM  Mylan's Generic Version of Advair Diskus Wins FDA Approval Zacks
Jan-31-19 07:23PM  J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study Zacks
04:06PM  6 Poorly Performing Stocks in Gurus' Portfolios GuruFocus.com
03:42PM  Mylan N.V. -- Moody's says FDA approval of generic Advair is credit positive for Mylan Moody's
02:59PM  Mylan Announces FDA Approval of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) PR Newswire
02:44PM  Bear Signal Just Flashed for EpiPen Producer Schaeffer's Investment Research
12:16PM  Exclusive: Teva's generic EpiPen launch stalls months after approval Reuters
09:30AM  Mylan (MYL) Jumps: Stock Rises 7.1% Zacks
07:50AM  Today's Research Reports on Trending Tickers: Mylan and Heron Therapeutics ACCESSWIRE
Jan-30-19 07:44PM  FDA OKs 1st generic version of popular Advair asthma inhaler Associated Press +7.13%
07:44PM  FDA OKs 1st generic version of popular Advair asthma inhaler Associated Press
04:34PM  FDA approves Mylan's generic of Advair asthma treatment Reuters
04:09PM  Mylan Pops After FDA Approves Its Knockoff Of Glaxo's Asthma Inhaler Investor's Business Daily
08:46AM  Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid Zacks
Jan-28-19 12:37PM  Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results Zacks
Jan-25-19 11:05AM  AbbVie expects steeper decline in Humira's overseas sales; shares fall Reuters
Jan-24-19 07:29PM  Can Allergan (AGN) Keep the Earnings Streak Alive in Q4? Zacks
Jan-23-19 08:47AM  With $500M in reserve, biotech cuts 49 jobs to focus on maturing drug pipeline American City Business Journals
Jan-22-19 06:07AM  The Zacks Analyst Blog Highlights: Mylan, Altice USA and Keysight Technologies Zacks
Jan-16-19 04:48PM  Adamis stock surges on release of EpiPen alternative MarketWatch
10:05AM  Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C Zacks
Jan-15-19 02:44PM  European nations weigh impact of Brexit on drug supplies Reuters
02:41PM  European nations weigh impact of Brexit on drug supplies Reuters
10:46AM  European nations weigh impact of Brexit on drug supplies Reuters
Jan-10-19 02:54PM  Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility Zacks
11:00AM  INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data Zacks
10:00AM  Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect Zacks
09:30AM  MYL vs. SUPN: Which Stock Is the Better Value Option? Zacks
Jan-08-19 09:10AM  Is Mylan (MYL) a Great Value Stock Right Now? Zacks
07:34AM  4 Oversold Stocks Ready to Rise Investopedia
Jan-04-19 06:42PM  Four Low P/E Stocks That Look Like Good Bets Barrons.com +5.91%
02:00PM  Should You Be Concerned About Mylan N.V.s (NASDAQ:MYL) ROE? Simply Wall St.
Jan-03-19 10:27AM  Ironwood/Allergan Settle Linzess Patent Litigation With Mylan Zacks
07:36AM  The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen Benzinga
Jan-02-19 11:41AM  Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the US Reuters
Dec-28-18 09:55AM  Generic Industry on Path to Recovery: 3 Hot Picks for 2019 Zacks
09:46AM  Will AbbVie (ABBV) Shares Regain Lost Momentum in 2019? Zacks
Dec-27-18 01:50PM  The Humira Overhang Cant Cast a Shadow on AbbVie Stock Forever InvestorPlace
Dec-26-18 03:34PM  2019 will be robust year for health care stocks, says Fre... CNBC Videos +5.72%
Dec-24-18 08:59AM  Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija Zacks
Dec-20-18 07:30AM  Mylan to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
07:00AM  Today's Research Reports on Trending Tickers: Bristol-Myers Squibb and Mylan ACCESSWIRE
Dec-17-18 10:45AM  Launch of Generic Lialda® Delayed-Release Tablets Expands Mylan's Gastroenterology Product Offering PR Newswire
10:30AM  Mylan Adds First Generic for Canasa® Rectal Suppository to Growing Gastroenterology Portfolio PR Newswire
Dec-14-18 12:32PM  Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus Zacks
Dec-13-18 11:54AM  Mylan says Sanofi loses Lantus insulin patent claims Reuters
11:14AM  Should Warren Buffett And You Buy More TEVA Stock Right Now? InvestorPlace
07:46AM  Mylan says patent office cancels Sanofi's Lantus patents Reuters
07:30AM  Sanofi's Formulation Patents on Multibillion-Dollar Lantus® are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan PR Newswire
Dec-11-18 03:03PM  Teva (TEVA) Stock Poised to Record Big Gains in 2019? Zacks
09:23AM  Generic Drugmakers Down on Allegations of Price Fixing Zacks
06:57AM  Generic-drug stocks slammed by report of expanded price-fixing probe MarketWatch
Dec-10-18 09:45AM  ATRS: Xyosted & Epi Pen Available for Sale Zacks Small Cap Research
Dec-07-18 05:32PM  Correction: Cheaper EpiPen Rival story Associated Press
Dec-06-18 11:33PM  Generic drugmaker Sandoz to sell alternative to EpiPen injectors MarketWatch
07:19PM  Novartis to launch Adamis' EpiPen rival in U.S. next year Reuters
07:45AM  Market Trends Toward New Normal in Hasbro, Spark Energy, QUALCOMM, Green Brick Partners, Mylan N.V, and Magellan Health Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Dec-05-18 12:51PM  Hedge Funds Are Dumping Mylan N.V. (MYL) Insider Monkey
09:30AM  Mylan (MYL) Down 9.5% Since Last Earnings Report: Can It Rebound? Zacks
09:14AM  Mylan Expands Recall of Valsartan to All Unexpired Lots Zacks
Dec-04-18 01:09PM  Mylan to recall all batches of blood pressure medicine valsartan in U.S. Reuters
11:45AM  Mylan to recall all batches of blood pressure medicine in U.S. Reuters
11:30AM  Mylan Expands its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to All Lots Within Expiry Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient PR Newswire
07:30AM  Mylan Expands Gastroenterology Portfolio with Launch of Generic for Prevacid® SoluTab Delayed-Release Orally Disintegrating Tablets PR Newswire
Dec-03-18 09:55AM  AbbVie Settles With Pfizer for Humira Biosimilar in U.S. Zacks
Nov-30-18 03:26PM  3 Beaten-Down Biotech Stocks to Buy Before the End of 2018 InvestorPlace
Nov-29-18 04:47PM  Theravance Pipeline Strong, Plans Yupelri Launch by Year End Zacks
Nov-28-18 08:53AM  New generic EpiPen offers no cost savings American City Business Journals
08:39AM  Teva (TEVA) Launches First Generic Version of Mylan's EpiPen Zacks
Nov-27-18 05:02PM  Teva to recall certain blood pressure medicine in U.S. Reuters
01:48PM  Teva prices EpiPen generic at $300, same price as Mylan generic Reuters
01:10PM  Teva prices EpiPen generic at $300, same price as Mylan generic Reuters
11:38AM  [$$] Teva Releases Generic EpiPen in Limited Doses in the U.S. The Wall Street Journal
10:34AM  3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far Zacks
Nov-26-18 11:57AM  Mylan to Present at Nasdaq's 39th London Investor Conference PR Newswire
Nov-25-18 09:35AM  9 Policy Catalysts For Health Care Investors To Watch Before Year's End Benzinga
Nov-22-18 08:31AM  J&J Loses Appeal to Halt Generic Zytiga Launch, Stock Down Zacks
Nov-21-18 03:21PM  Heat Biologics Takes Beating After Pricing $12 Million Stock Offering TheStreet.com
02:05PM  J&J Falls After Failing to Block Generic Zytiga Cancer Drug Bloomberg
10:04AM  Mylan Recalls Valsartan Lots, Gets FDA Warning for Facility Zacks
08:04AM  The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO Benzinga
07:07AM  FDA warns Mylan over Morgantown plant American City Business Journals
07:05AM  Today's Research Reports on Trending Tickers: Mylan and Teva Pharmaceutical Industries ACCESSWIRE
Nov-20-18 06:49PM  Mylan recalls batches of blood pressure medicine in U.S. Reuters
06:30PM  Mylan gets FDA warning letter over infractions at West Virginia plant Reuters
05:07PM  Mylan recalls batches of blood pressure medicine in U.S. Reuters
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; anti-retroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology, oncology, and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and Dymista, which is used for the treatment of seasonal allergic rhinitis. Further, it markets OTC products, including Cold-EEZE, Midnite, and Vivarin. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, group purchasing organizations, and government entities; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. Mylan N.V. has collaboration and license agreements with Pfizer Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., and Biocon Ltd. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CAMERON WENDYDirectorJun 29Option Exercise0.004,028076,735Jul 03 04:35 PM
Campbell PaulSee RemarksMar 06Sale44.017,030309,39017,522Mar 06 08:32 PM
COURY ROBERT JDirectorMar 06Sale43.4150,0002,170,685271,115Mar 06 08:10 PM
Campbell PaulSee RemarksMar 04Option Exercise0.001,081018,052Mar 06 08:32 PM
Mauro AnthonyChief Commercial OfficerMar 04Option Exercise0.0015,9360153,443Mar 06 08:29 PM
Malik RajivPresidentMar 04Option Exercise0.0040,7960549,146Mar 06 08:27 PM
BRESCH HEATHER MChief Executive OfficerMar 04Option Exercise0.0066,2920564,408Mar 06 08:26 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002200220Mar 06 08:32 PM
Campbell PaulSee RemarksMar 03Option Exercise0.00831017,054Mar 06 08:32 PM
Parks Kenneth ScottChief Financial OfficerMar 03Option Exercise0.003,98506,800Mar 06 08:30 PM
Mauro AnthonyChief Commercial OfficerMar 03Option Exercise0.005,5340140,712Mar 06 08:29 PM
Malik RajivPresidentMar 03Option Exercise0.0012,3950516,146Mar 06 08:27 PM
Gallagher Daniel Martin JrChief Legal OfficerMar 03Option Exercise0.008,21808,218Mar 06 08:26 PM
BRESCH HEATHER MChief Executive OfficerMar 03Option Exercise0.0020,1420510,917Mar 06 08:26 PM
Vollebregt Sjoerd SDirectorMar 03Option Exercise0.004,23004,230Mar 06 08:25 PM
VANDERVEEN RANDALL LDirectorMar 03Option Exercise0.003,653043,342Mar 06 08:24 PM
PARRISH MARK WDirectorMar 03Option Exercise0.003,653038,920Mar 06 08:22 PM
HIGGINS MELINA EDirectorMar 03Option Exercise0.003,65309,092Mar 06 08:22 PM
DIMICK NEIL FDirectorMar 03Option Exercise0.003,653046,142Mar 06 08:18 PM
Lyons Dillon JoEllenDirectorMar 03Option Exercise0.003,653011,164Mar 06 08:13 PM
Cindrich Robert JDirectorMar 03Option Exercise0.003,653020,604Mar 06 08:09 PM
CAMERON WENDYDirectorMar 03Option Exercise0.003,653074,232Mar 06 08:08 PM
Mauro AnthonyChief Commercial OfficerMar 02Option Exercise22.664,757107,794147,435Mar 06 08:29 PM
Malik RajivPresidentMar 02Sale40.9150,0002,045,695503,751Mar 06 08:27 PM
COURY ROBERT JDirectorMar 02Sale40.10150,0006,014,625321,115Mar 06 08:10 PM
Mauro AnthonyChief Commercial OfficerMar 02Sale40.3512,257494,570135,178Mar 06 08:29 PM